Torrent Pharmaceuticals Limited , a leading Indian pharmaceutical company, has announced robust financial results for the first quarter, showcasing significant growth across key markets and financial metrics.

Financial Highlights

• Revenue reached Rs. 3,178.00 crores, marking an 11% year-on-year growth
• Operating EBITDA increased by 14% to Rs. 1,032.00 crores
• Net profit after tax surged by 20% to Rs. 548.00 crores
• Gross margin remained steady at 76%
• Operating EBITDA margin stood at 32.5%

Market Performance

India

• India revenues grew by 11% to Rs. 1,811.00 crores
• Chronic business outperformed with 13% growth compared to 9% IPM growth
• 21 brands featured in the Top 500 brands of Indian Pharmaceutical Market (IPM)
• 14 brands achieved sales exceeding Rs. 100.00 crores

Brazil

• Brazil revenues increased by 11% to Rs. 218.00 crores
• Constant currency revenues rose by 16% to R$ 143.00 million
• Torrent's growth rate of 14% outpaced the market growth of 5%
• 62 products currently under ANVISA review

Germany

• Germany revenues grew by 9% to Rs. 308.00 crores
• Constant currency revenues increased by 1% to EUR 32.00 million
• Growth was impacted by supply disruptions from a third-party supplier

United States

• US business revenues surged by 19% to Rs. 308.00 crores
• Constant currency revenues increased by 16% to $36.00 million
• Recent product launches achieved targeted market shares

R&D Investment

Torrent Pharmaceuticals continued its focus on research and development:

• R&D spend increased by 16% to Rs. 157.00 crores
• R&D expenditure accounted for 5% of total revenues

Company Overview

Torrent Pharmaceuticals Limited, the flagship company of the Torrent Group, reported annual revenues exceeding Rs. 11,500.00 crores. The company maintains a strong position in the Indian pharmaceutical market:

• Ranked 7th overall in the Indian Pharmaceuticals Market
• Among the Top 5 in key therapeutic segments: Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), and Cosmo-Dermatology
• Specialty-focused with approximately 76% of India revenues from chronic and sub-chronic therapies
• Present in over 50 countries
• Ranked 1st among Indian pharma companies in Brazil and Germany
• Operates 8 manufacturing facilities, including 5 USFDA-approved sites
• Employs over 750 scientists in state-of-the-art R&D infrastructure

Torrent Pharmaceuticals' strong Q1 performance underscores its successful strategy of focusing on chronic therapies and expanding its presence in key international markets. The company's continued investment in R&D and its robust pipeline of products under review suggest a positive outlook for future growth and innovation in the pharmaceutical sector.

Torrent Pharmaceuticals Limited , a leading Indian pharmaceutical company, has announced robust financial results for the first quarter, along with a significant leadership change.

Strong Financial Performance

The company reported impressive growth in its Q1 results:

• Revenue reached Rs. 3,178.00 crores, marking an 11% year-over-year increase
• Operating EBITDA rose by 14% to Rs. 1,032.00 crores
• Net profit after tax grew by 20% to Rs. 548.00 crores
• R&D spend increased by 16% to Rs. 157.00 crores

The company maintained a strong operating EBITDA margin of 32.50% and a gross margin of 76.00%.

Key Market Performance

Torrent Pharmaceuticals demonstrated growth across its major markets:

Appointment of New Managing Director

In a significant move, Torrent Pharmaceuticals' shareholders have approved the appointment of Aman Mehta as Managing Director and Whole-time Key Managerial Personnel for a 5-year term beginning August 1, 2025.

Aman Mehta's Background and Achievements

Aman Mehta brings a wealth of experience to his new role:

• Holds an economics degree from Boston University and an MBA from Columbia University
• Over 10 years of leadership experience across Torrent's Power and Pharma divisions
• Key achievements during his tenure as Whole-time Director include:
  • Expanding the field force from 3,600 to 6,400 medical representatives
  • Improving cardiac portfolio performance
  • Elevating the diabetes portfolio ranking from 11th to 6th position
  • Launching the Consumer Health Division
  • Overseeing R&D and operations functions
  • Successfully integrating acquisitions, including Unichem and Curatio Healthcare

Future Outlook

With strong financial results and new leadership in place, Torrent Pharmaceuticals is well-positioned for continued growth. The company's focus on chronic therapies, which account for about 76% of its India revenues, and its strong presence in international markets, particularly in Brazil and Germany, provide a solid foundation for future expansion.

The appointment of Aman Mehta as Managing Director is expected to bring fresh perspectives and strategic initiatives to drive the company's growth in the coming years. His experience in both the Power and Pharma sectors of the Torrent Group, coupled with his track record of successful acquisitions and market expansion, suggests a promising future for Torrent Pharmaceuticals.

As the pharmaceutical landscape continues to evolve, Torrent's commitment to R&D investment and focus on key therapeutic areas position it well to capitalize on emerging opportunities in the global pharmaceutical market.